Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
Top Cited Papers
- 24 February 2011
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 14 (3), 164-176
- https://doi.org/10.1016/j.drup.2011.01.004
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010
- Echinocandin Susceptibility Testing ofCandidaSpecies: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest MediaAntimicrobial Agents and Chemotherapy, 2010
- Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target SpeciesAntimicrobial Agents and Chemotherapy, 2009
- Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2008
- In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2008
- Acquired resistance to echinocandins in Candida albicans: case report and reviewJournal of Antimicrobial Chemotherapy, 2007
- In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003
- In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole ResistanceJournal of Clinical Microbiology, 2002
- Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal CandidiasesAntimicrobial Agents and Chemotherapy, 2002